Agilent Manuals

This document describes the features of ZORBAX StableBond C8, which has a sterically protected bonded phase that allows stable operation at low mobile-phase pH. ZORBAX SB-C8 separates basic compounds with good resolution and peak shape using simple mobile phases. The document also provides the conditions for using ZORBAX Rx/SB-C8 in pharmaceutical applications.

This document describes that Agilent Technologies' Rx-Silica highlights good peak shape of basic compounds in opiate drugs. These basic compounds have poor peak shape on many reversed-phase columns. ZORBAX Rx-SIL has an extremely homogeneous silica surface with uniform associated silanols and low acidity. ZORBAX Rx and StableBond columns show significantly reduced band tailing and improved column efficiency when analyzing basic compounds.

This document describes a method for separating local anesthetics on different bonded-phase ZORBAX columns and analyzes the selectivity of the separations.

This document describes the separation performance of ZORBAX XDB-C8 for Procainamides and metabolites at a pH of 7.0 or higher. It provides good peak shape and resolution, making it suitable for pharmaceutical applications.

This document describes the separation of cephalosporins on Agilent ZORBAX XDB-C8 column.

This document describes a method for high-resolution chiral separation of R- and S-Norfluoxetine using Ultron ES-Pepsin. The method achieves excellent separation and extends the column's useful lifetime.

The document describes the separation method for extracting morphine and its metabolites from blood plasma. Good resolution and peak shape for morphine and two metabolites can be achieved using ZORBAX SB-C18 at moderate pH. Morphine and the metabolite morphine-6-glucuronide can be sensitively detected using electrochemical detection, while morphine-3-glucuronide can be sensitively detected using fluorescence.

This document describes the separation method for tricyclic antidepressants and their metabolites. It explains that good peak shapes can be obtained for very basic compounds at pH 6.2 by adding TEA. The document also suggests that changing the pore-size and surface area of the column packing can help achieve the desired separation. Specific analysis conditions and methods are provided.

This document describes the high-resolution separation method and characteristics of nonsteroidal anti-inflammatory drugs, as well as the narrow-bore column configuration suitable for LC/MS applications. The Eclipse XDB-C8 column is capable of separating acidic, basic, and neutral molecules with good peak shape. Specific analysis conditions and the pKa values of the drugs are provided.

This document describes the rapid analysis of dexamethasone using the USP method. By choosing a ZORBAX Rapid-Resolution column configuration, analysis time is reduced by 70% and solvent consumption is subsequently reduced. Improved performance can be achieved by selecting an alternative column configuration.

This application notes updates the USP methods for metronidazole to improve column efficiency and sensitivity.

The document describes the method and advantages of using ZORBAX Eclipse XDB-C18 for HPLC analysis. By using ZORBAX Eclipse XDB-C18, improved peak shape, higher separation efficiency, greater sensitivity, reduced analysis time, reduced back pressure, and reduced solvent use per analysis can be achieved. The performance of this product surpasses the requirements of USP, with a higher number of theoretical plates and a closer tailing factor to the ideal value.